This study is to examine the superiority of the combined treatments of transdiagnostic cognitive-behavior therapy (Unified Protocol; UP) and Treatment-As-Usual in comparison with the waiting-list with Treatment-As-Usual in the reduction of depressive and anxiety symptoms among depressive and anxiety disorders.

Unified Protocol is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. During this treatment period, the participants continue the Treatment As Usual.

Behavioral: Unified Protocol with Treatment As Usual

Unified Protocol(UP) is a transdiagnostic cognitive-behavioral therapy for depressive and anxiety disorders, which is developed by Dr. Barlow and his colleagues at Boston university.

UP is weekly, face to face, individual psychotherapy consisting of 9 to 20 sessions. Average session number is 16 sessions. Contents of the treatment includes motivational enhancement, psychoeducation of treatment rationale and emotion, emotion awareness training, cognitive reappraisal, avoidance and emotion driven behaviors, interoceptive exposure and emotion exposure.

Other Name: Cognitive Behavioral Therapy

Other: Treatment As Usual

Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.

Waitlist Control with Treatment As Usual

Waitlist participants will not receive treatment during a 20-week waitlist period, but will receive the unified protocol immediately following the 20 week waiting period. During the waitlist period, the waitlist participants continue the treatment as usual.

Other: Treatment As Usual

Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.

Detailed Description:

Participants with depressive or anxiety disorders will be randomized to either Unified Protocol with Treatment-As-Usual or Wail-list with Treatment-As-Usual. Intervention period will be 20-week and the follow-up period will be 43 week from registration.

Depressive and anxiety symptoms is mild or more severe (GRID-HAMD >= 8).

Ages 20 years or older, and 65 years or younger at screening.

Subjects who give full consent in the participation of the study.

Exclusion Criteria:

No alcohol or substance use disorder in 6 months prior to the screening assessed by SCID

No current manic episode or current schizophrenia and other psychotic disorders at baseline assessed by SCID

No serious suicidal ideation at baseline (GRID-HAMD Item3 severity is 3 or higher.)

No life-threatening, severe or unstable physical disorders or major cognitive deficits at baseline.

Evidence of unable to participate half or more of the intervention phase.

No structured psychotherapy during at baseline.

Other relevant reason decided by the investigators.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02003261